ALX Oncology Holdings Inc.

formerly ALX OncologyIPO

ALX Oncology • A Synergistic Approach to Cancer Treatment

Public · South San Francisco, United States · Founded 2015

Employees
51–200
Founded
2015
Business Model
B2B
Type
Public

About

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, with a focus on immuno-oncology. The company's lead program, evorpacept, is designed to block the CD47 'don't eat me' signal, enabling the immune system to recognize and destroy cancer cells across multiple tumor types. Headquartered in South San Francisco, California, ALX Oncology went public in July 2020 and is led by a team of experienced oncology drug developers committed to delivering next-generation breakthrough cancer treatments.

Summary

ALX Oncology Holdings Inc. is a Biotech company based in South San Francisco, United States, founded in 2015.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJul 2020
$200.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ALX Oncology Holdings Inc. on Indexed.vc
<a href="https://indexed.vc/companies/alx-oncology-holdings-inc"><img src="https://indexed.vc/api/badge/company/alx-oncology-holdings-inc" alt="ALX Oncology Holdings Inc. on Indexed.vc" width="260" height="76" /></a>